TAT Technologies Ltd美股招股说明书(2025-05-28版)

SUBJECT TO COMPLETION, DATED MAY 28, 2025 Prospectus Supplement(To Prospectus dated April 25, 2025) TAT TECHNOLOGIES LTD. 4,150,000 Ordinary Shares We are offering for sale 1,625,000 ordinary shares. The selling shareholders identified in this prospectus supplementare offering an additional 2,525,000 ordinary shares. We will not receive any of the proceeds from the sale of shares beingoffered by the selling shareholders. Our ordinary shares are listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “TATT” and on the Tel AvivStock Exchange (“TASE”) under the symbol “TATT.”On May 27, 2025, the last reported sale price of our ordinary shares onNasdaq was $31.22 per share, and the last reported sale price of our ordinary shares on TASE was NIS 109.00 per ordinaryshare, or approximately $30.82 per ordinary share. Public offering price (1)See “Underwriting” for additional information regarding underwriter compensation. The underwriters may also exercise their option to purchase up to an additional 242,298 ordinary shares from us andan additional 380,202 ordinary shares from the selling shareholders at the public offering price, less underwriting discounts andcommissions, for 30days after the date of this prospectus supplement. Investing in our ordinary shares involves substantial risk. See “Risk Factors” on page S-4 of this prospectussupplement and in the documents incorporated by reference in this prospectus supplement concerning factors youshould consider before investing in the ordinary shares. None of the Securities and Exchange Commission, the Israel Securities Authority or any state securitiescommission has approved or disapproved of the ordinary shares being offered by this prospectus, or determined if thisprospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the ordinary shares to purchasers on or about, 2025. Joint Book-running Managers Passive Book-running Managers The Benchmark Company Lake Street TABLE OF CONTENTS Prospectus Supplement ABOUT THIS PROSPECTUS SUPPLEMENT In this prospectus supplement, “we”, “us”, “our”, the “Company” and “TAT” refer to TAT Technologies Ltd. and itssubsidiaries. This document consists of two parts.The first part is this prospectus supplement, which is part of a registrationstatement(No.333-286699)that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registrationprocess. The second part is the accompanying prospectus, which is part of the registration statement, under which we registered (i)theoffering on behalf of the selling shareholders of up to 2,905,202 of our ordinary shares for sale from time to time in one or moreofferings, and (ii)the offering by us of up to $70,000,000 of ordinary shares, warrants and debt securities for sale from time to time inone or more offerings. This prospectus supplement provides specific information about the offering by us of 1,625,000 ordinary sharesand by the selling shareholders of 2,525,000 ordinary shares under the shelf registration statement, in addition to informationconcerning the option granted by us. The accompanying prospectus provides more general information regarding the securities thatmay be offered by us or any selling shareholder, some of which may not apply to this offering. Generally, when we refer to theprospectus, we are referring to both this prospectus supplement and the accompanying prospectus. This prospectus supplement and theinformation incorporated by reference in this prospectus supplement adds to, updates and, where applicable, modifies and supersedesinformation contained or incorporated by reference in the accompanying prospectus. If there is any inconsistency between theprospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus supplement. Before you invest in our ordinary shares, you should carefully read this prospectus supplement, the accompanying prospectus,any free writing prospectus prepared by us, and the information that we incorporate by reference into those documents. In the eventthat there are any differences or inconsistencies between this prospectus supplement, the accompanying prospectus, and theinformation incorporated by reference herein and therein, you should only rely on the information contained in the document with thelatest date. Please refer to the information and documents listed and described under the heading “Where You Can Find MoreInformation; Incorporation of Information by Reference” in the accompanying prospectus. We, the selling shareholder, and the underwriters have not authorized anyone to provide additional information orinformation different from that contained in this prospectus, any amendment or supplement to this prospectus or in any freewriting prospectus prepared by us or on our behalf or to which we may have referred you. We, the selling shareholder, and theunderwriter